ロード中...
Systemic immunotherapy with micellar resiquimod-polymer conjugates triggers a robust antitumor response in a breast cancer model
Resiquimod is an immunopotent toll-like receptor 7/8 agonist with anti-tumor activity. Despite being potent against skin cancers, it’s poorly tolerated systemically due to toxicity. Integrating resiquimod into nanoparticles presents an avenue to circumvent the toxicity problem. Herein, the preparati...
保存先:
| 出版年: | Adv Healthc Mater |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8153207/ https://ncbi.nlm.nih.gov/pubmed/33646600 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/adhm.202100008 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|